Mannkind, Game-Chancer in Sachen Diabetik? (Seite 256)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 01.05.24 22:12:10 von
neuester Beitrag 01.05.24 22:12:10 von
Beiträge: 6.832
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 35
Gesamt: 594.015
Gesamt: 594.015
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: MNKD
4,3850
USD
+1,04 %
+0,0450 USD
Letzter Kurs 19:12:53 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,7850 | +96,11 | |
| 2,0500 | +64,00 | |
| 1,2099 | +34,52 | |
| 0,9500 | +33,67 | |
| 1,6300 | +28,35 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,0500 | -14,06 | |
| 1,2029 | -14,15 | |
| 1,6100 | -15,26 | |
| 3,5000 | -26,24 | |
| 11,500 | -29,23 |
Beitrag zu dieser Diskussion schreiben
Feedback
Dr. Kendall ist eine Koryphäe im Diabetisbereich, tausende unbezahlbare Kontakte zu den KOL, super gemacht Mike!
Ihr habt all einen zu kurzen Zeitraum für Afrezza, 2-3 Jahre dann sind wird weltweit verbreitet und zweistellig!
Ihr habt all einen zu kurzen Zeitraum für Afrezza, 2-3 Jahre dann sind wird weltweit verbreitet und zweistellig!
Antwort auf Beitrag Nr.: 56.950.949 von question-mark am 06.02.18 16:24:02...mh, war das nicht Castagna, der in Westlake Village mit Robert Bradway gesehen wurde ??..
Antwort auf Beitrag Nr.: 56.950.826 von pulloverschaf am 06.02.18 16:15:55ich pushe jetzt mal:
der Kurs wird gedeckelt, damit Lilly nicht so viel für die Übernahme bezahlen muss
der Kurs wird gedeckelt, damit Lilly nicht so viel für die Übernahme bezahlen muss
Antwort auf Beitrag Nr.: 56.949.029 von question-mark am 06.02.18 14:17:01Das wäre was 👍😳 dann würde es explodieren. Aber so wie es jetzt derzeit läuft 🤔
Antwort auf Beitrag Nr.: 56.948.894 von Aurum2010 am 06.02.18 14:03:27dann soll er mal schnell einen deal mit Lilly einfädeln 
Trading Spotlight
David Kendall Joins MannKind as Chief Medical Officer
WESTLAKE VILLAGE, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that David M. Kendall, MD, will join the company as Chief Medical Officer and assume full responsibility for leading MannKind's scientific research, clinical development, regulatory, and medical affairs activity, effective February 12. Dr. Kendall will report directly to Michael Castagna, Pharm.D., Chief Executive Officer, and will join the company's executive leadership team. He will be based out of MannKind's Westlake Village, California headquarters.
"David is a world renowned diabetes expert and represents an important addition to our executive leadership team," said Castagna, Chief Executive Officer of MannKind. "His extensive experience in diabetes research, development, and clinical care in both U.S. and international markets, will be instrumental in helping us achieve the growth potential that we believe Afrezza® clearly possesses."
Dr. Kendall's career includes over 30 years of experience in diabetes and metabolism research, clinical management, research, and policy advocacy. Most recently, he served as Research Physician and Vice President of Global Medical Affairs for Lilly Diabetes, and during that time was responsible for all medical affairs activities and guided research and development strategy across multiple geographies. In this role, he worked to re-establish Lilly Diabetes as a world class medical organization — and added to his extensive experience with both injected and mealtime insulins, as well as devices and continuous glucose monitors. Prior to joining Eli Lilly, Dr. Kendall served as Chief Scientific and Medical Officer at the American Diabetes Association, where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. Earlier in his career, Dr. Kendall served as Medical Director at the International Diabetes Center, and the Park Nicollet Clinic, as well as at Amylin Pharmaceuticals. He received his M.D. and completed his Post Graduate Medical Training at the University of Minnesota, and earned a B.A. in Biology from St. Olaf College.
"The research and clinical response to Afrezza as a mealtime insulin supports ongoing efforts to establish this product as the standard of care for those living with type 1 or type 2 diabetes," said Dr. Kendall. "Afrezza is the only inhaled fast-acting mealtime insulin on the market, and offers the right patients a flexible, safe, and effective treatment option. I'm thrilled to join MannKind, and look forward to being part of a company that has the potential to transform the lives of so many people that are living with diabetes."
WESTLAKE VILLAGE, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that David M. Kendall, MD, will join the company as Chief Medical Officer and assume full responsibility for leading MannKind's scientific research, clinical development, regulatory, and medical affairs activity, effective February 12. Dr. Kendall will report directly to Michael Castagna, Pharm.D., Chief Executive Officer, and will join the company's executive leadership team. He will be based out of MannKind's Westlake Village, California headquarters.
"David is a world renowned diabetes expert and represents an important addition to our executive leadership team," said Castagna, Chief Executive Officer of MannKind. "His extensive experience in diabetes research, development, and clinical care in both U.S. and international markets, will be instrumental in helping us achieve the growth potential that we believe Afrezza® clearly possesses."
Dr. Kendall's career includes over 30 years of experience in diabetes and metabolism research, clinical management, research, and policy advocacy. Most recently, he served as Research Physician and Vice President of Global Medical Affairs for Lilly Diabetes, and during that time was responsible for all medical affairs activities and guided research and development strategy across multiple geographies. In this role, he worked to re-establish Lilly Diabetes as a world class medical organization — and added to his extensive experience with both injected and mealtime insulins, as well as devices and continuous glucose monitors. Prior to joining Eli Lilly, Dr. Kendall served as Chief Scientific and Medical Officer at the American Diabetes Association, where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. Earlier in his career, Dr. Kendall served as Medical Director at the International Diabetes Center, and the Park Nicollet Clinic, as well as at Amylin Pharmaceuticals. He received his M.D. and completed his Post Graduate Medical Training at the University of Minnesota, and earned a B.A. in Biology from St. Olaf College.
"The research and clinical response to Afrezza as a mealtime insulin supports ongoing efforts to establish this product as the standard of care for those living with type 1 or type 2 diabetes," said Dr. Kendall. "Afrezza is the only inhaled fast-acting mealtime insulin on the market, and offers the right patients a flexible, safe, and effective treatment option. I'm thrilled to join MannKind, and look forward to being part of a company that has the potential to transform the lives of so many people that are living with diabetes."
Antwort auf Beitrag Nr.: 56.943.380 von peppino23 am 06.02.18 08:00:17
Mal schauen ev. wirst Du ja heute positiv überrascht
Zitat von peppino23: Da bin ich vollkommen deiner Meinung ! Dafür kommen wir heute dran
Gestern mussten die retten was es zu retten gab. Für MKD blieb da keine Zeit. Aber schön zu sehen, dass wir uns gut halten könnten, wenn es diese Ratten nicht gäbe!
Mal schauen ev. wirst Du ja heute positiv überrascht
Antwort auf Beitrag Nr.: 56.940.992 von Aurum2010 am 05.02.18 22:04:01Da bin ich vollkommen deiner Meinung ! Dafür kommen wir heute dran
Gestern mussten die retten was es zu retten gab. Für MKD blieb da keine Zeit. Aber schön zu sehen, dass wir uns gut halten könnten, wenn es diese Ratten nicht gäbe!
Gestern mussten die retten was es zu retten gab. Für MKD blieb da keine Zeit. Aber schön zu sehen, dass wir uns gut halten könnten, wenn es diese Ratten nicht gäbe!
Antwort auf Beitrag Nr.: 56.940.068 von Magnetfeldfredy am 05.02.18 21:19:13
Heute gab es bessere Titel zum shorten bzw. hatten die Shorts keine Zeit für MNKD
Zitat von Magnetfeldfredy: Mannkind hält sich bei dem Crash super!
Heute gab es bessere Titel zum shorten bzw. hatten die Shorts keine Zeit für MNKD
Antwort auf Beitrag Nr.: 56.940.068 von Magnetfeldfredy am 05.02.18 21:19:13Biotechs halten sich da immer besser, wurden ja bei guten Kursen richtig runtergeprügelt! Wo würden wir stehen, wenn wir die Kursanstiege mitgemacht hätten - Frage ?
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
